{"id":{"repo_id":"goteborg","oai_identifier":"oai:gupea.ub.gu.se:2077/44864"},"canonical_url":"https://search.dev.ndltd.org/etd/goteborg/oai:gupea.ub.gu.se:2077/44864","repository":{"repo_id":"goteborg","name":"Gothenburg University","base_url":"https://gupea.ub.gu.se/oai/request"},"display":{"title":"The Role of Insulin and Insulin-like Ischemic Stroke and Cognitive Impairment","abstract":"Background and aims: Insulin, insulin-like growth factor-I (IGF-I), and the six high-affinity IGF-binding proteins (IGFBPs) play an important role in growth, metabolism and regeneration throughout the entire life span. In contrast, the role of IGF-II in adult life has been unclear. Animal studies have demonstrated that altered brain activity of the insulin/IGF-system is associated with reduced cognitive function and worse outcome after experimentally induced stroke and this is reversed by IGF-I-treatment. The overall aim of this thesis was to determine whether the insulin/IGF-I system is of importance for outcome of ischemic stroke (IS) also in humans and whether insulin and insulin-like peptides are dysregulated in patients with Alzheimer’s disease (AD). Patients and methods: Two well-characterized clinical cohorts were studied. In SAHLSIS (Sahlgrenska Academy Study on Ischemic Stroke; originally 600 IS patients and 600 population-based controls), characterization of patients after IS included serum samples and stroke scales. Furthermore, serum and cerebrospinal fluid (CSF) levels of insulin, IGF-I, and IGF-II were determined in a cross-sectional study of patients (n=60) with AD and other forms of cognitive impairment, and healthy controls (n=20). Results: In Paper I, high serum IGF-I concentrations were associated with better improvement of functional independence in SAHLSIS. In Paper II, analyses of single-nucleotide polymorphisms (SNPs) in the IGF1 gene showed that the major allele of rs7136446 was associated with favorable post-stroke outcome after 2 years. In Paper III, insulin resistance was associated with functional outcome, especially in patients with cryptogenic stroke. In Paper IV, serum but not CSF levels of IGF-I were increased in patients with AD whereas insulin levels were unchanged both in serum and CSF. In Paper V, CSF IGF-II level was increased in male but not in female patients with AD. Conclusions: The IGF-I/insulin system is associated with functional outcome after ischemic stroke. Furthermore, levels of IGF-I and IGF-II are dysregulated in Alzheimer’s disease.","abstract_html":"Background and aims: Insulin, insulin-like growth factor-I (IGF-I), and the six high-affinity IGF-binding proteins (IGFBPs) play an important role in growth, metabolism and regeneration throughout the entire life span. In contrast, the role of IGF-II in adult life has been unclear. Animal studies have demonstrated that altered brain activity of the insulin/IGF-system is associated with reduced cognitive function and worse outcome after experimentally induced stroke and this is reversed by IGF-I-treatment. The overall aim of this thesis was to determine whether the insulin/IGF-I system is of importance for outcome of ischemic stroke (IS) also in humans and whether insulin and insulin-like peptides are dysregulated in patients with Alzheimer’s disease (AD). Patients and methods: Two well-characterized clinical cohorts were studied. In SAHLSIS (Sahlgrenska Academy Study on Ischemic Stroke; originally 600 IS patients and 600 population-based controls), characterization of patients after IS included serum samples and stroke scales. Furthermore, serum and cerebrospinal fluid (CSF) levels of insulin, IGF-I, and IGF-II were determined in a cross-sectional study of patients (n=60) with AD and other forms of cognitive impairment, and healthy controls (n=20). Results: In Paper I, high serum IGF-I concentrations were associated with better improvement of functional independence in SAHLSIS. In Paper II, analyses of single-nucleotide polymorphisms (SNPs) in the IGF1 gene showed that the major allele of rs7136446 was associated with favorable post-stroke outcome after 2 years. In Paper III, insulin resistance was associated with functional outcome, especially in patients with cryptogenic stroke. In Paper IV, serum but not CSF levels of IGF-I were increased in patients with AD whereas insulin levels were unchanged both in serum and CSF. In Paper V, CSF IGF-II level was increased in male but not in female patients with AD. Conclusions: The IGF-I/insulin system is associated with functional outcome after ischemic stroke. Furthermore, levels of IGF-I and IGF-II are dysregulated in Alzheimer’s disease.","abstract_has_math":false,"creators":["Åberg, Daniel"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2016,"date_issued":"2016-11-02","date_published":"2016-11-02","updated_at":"2026-08-21T22:21:56Z","subjects":["Ischemic Stroke (IS)","Alzheimer´s disease (AD)","Cognitive Impairment","Dementia","Insulin-like Growth Factor I (IGF-I)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2077/44864","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"source_record":{"url":"https://gupea.ub.gu.se/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Agupea.ub.gu.se%3A2077%2F44864","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Åberg, Daniel"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2016-11-02T10:20:18Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2016-11-02T10:20:18Z"]},{"key":"dc:date.issued","label":"Date","values":["2016-11-02"]},{"key":"dc:type","label":"Dc Type","values":["text"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Ischemic Stroke (IS)","Alzheimer´s disease (AD)","Cognitive Impairment","Dementia","Insulin-like Growth Factor I (IGF-I)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/2077/44864"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Background and aims: Insulin, insulin-like growth factor-I (IGF-I), and the six high-affinity IGF-binding proteins (IGFBPs) play an important role in growth, metabolism and regeneration throughout the entire life span. In contrast, the role of IGF-II in adult life has been unclear. Animal studies have demonstrated that altered brain activity of the insulin/IGF-system is associated with reduced cognitive function and worse outcome after experimentally induced stroke and this is reversed by IGF-I-treatment. The overall aim of this thesis was to determine whether the insulin/IGF-I system is of importance for outcome of ischemic stroke (IS) also in humans and whether insulin and insulin-like peptides are dysregulated in patients with Alzheimer’s disease (AD). Patients and methods: Two well-characterized clinical cohorts were studied. In SAHLSIS (Sahlgrenska Academy Study on Ischemic Stroke; originally 600 IS patients and 600 population-based controls), characterization of patients after IS included serum samples and stroke scales. Furthermore, serum and cerebrospinal fluid (CSF) levels of insulin, IGF-I, and IGF-II were determined in a cross-sectional study of patients (n=60) with AD and other forms of cognitive impairment, and healthy controls (n=20). Results: In Paper I, high serum IGF-I concentrations were associated with better improvement of functional independence in SAHLSIS. In Paper II, analyses of single-nucleotide polymorphisms (SNPs) in the IGF1 gene showed that the major allele of rs7136446 was associated with favorable post-stroke outcome after 2 years. In Paper III, insulin resistance was associated with functional outcome, especially in patients with cryptogenic stroke. In Paper IV, serum but not CSF levels of IGF-I were increased in patients with AD whereas insulin levels were unchanged both in serum and CSF. In Paper V, CSF IGF-II level was increased in male but not in female patients with AD. Conclusions: The IGF-I/insulin system is associated with functional outcome after ischemic stroke. Furthermore, levels of IGF-I and IGF-II are dysregulated in Alzheimer’s disease."]},{"key":"dc:title","label":"Title","values":["The Role of Insulin and Insulin-like Ischemic Stroke and Cognitive Impairment"]}]}],"canonical_facts":{"dc:creator":["Åberg, Daniel"],"dc:date.accessioned":["2016-11-02T10:20:18Z"],"dc:date.available":["2016-11-02T10:20:18Z"],"dc:date.issued":["2016-11-02"],"dc:description.abstract":["Background and aims: Insulin, insulin-like growth factor-I (IGF-I), and the six high-affinity IGF-binding proteins (IGFBPs) play an important role in growth, metabolism and regeneration throughout the entire life span. In contrast, the role of IGF-II in adult life has been unclear. Animal studies have demonstrated that altered brain activity of the insulin/IGF-system is associated with reduced cognitive function and worse outcome after experimentally induced stroke and this is reversed by IGF-I-treatment. The overall aim of this thesis was to determine whether the insulin/IGF-I system is of importance for outcome of ischemic stroke (IS) also in humans and whether insulin and insulin-like peptides are dysregulated in patients with Alzheimer’s disease (AD). Patients and methods: Two well-characterized clinical cohorts were studied. In SAHLSIS (Sahlgrenska Academy Study on Ischemic Stroke; originally 600 IS patients and 600 population-based controls), characterization of patients after IS included serum samples and stroke scales. Furthermore, serum and cerebrospinal fluid (CSF) levels of insulin, IGF-I, and IGF-II were determined in a cross-sectional study of patients (n=60) with AD and other forms of cognitive impairment, and healthy controls (n=20). Results: In Paper I, high serum IGF-I concentrations were associated with better improvement of functional independence in SAHLSIS. In Paper II, analyses of single-nucleotide polymorphisms (SNPs) in the IGF1 gene showed that the major allele of rs7136446 was associated with favorable post-stroke outcome after 2 years. In Paper III, insulin resistance was associated with functional outcome, especially in patients with cryptogenic stroke. In Paper IV, serum but not CSF levels of IGF-I were increased in patients with AD whereas insulin levels were unchanged both in serum and CSF. In Paper V, CSF IGF-II level was increased in male but not in female patients with AD. Conclusions: The IGF-I/insulin system is associated with functional outcome after ischemic stroke. Furthermore, levels of IGF-I and IGF-II are dysregulated in Alzheimer’s disease."],"dc:identifier.uri":["http://hdl.handle.net/2077/44864"],"dc:language.iso":["eng"],"dc:subject":["Ischemic Stroke (IS)","Alzheimer´s disease (AD)","Cognitive Impairment","Dementia","Insulin-like Growth Factor I (IGF-I)"],"dc:title":["The Role of Insulin and Insulin-like Ischemic Stroke and Cognitive Impairment"],"dc:type":["text"]},"updated_at":"2026-08-21T22:21:56Z"}